Patents by Inventor Hongchang Qu
Hongchang Qu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220193245Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: ApplicationFiled: December 17, 2021Publication date: June 23, 2022Inventors: Tamer COSKUN, Hongchang QU
-
Publication number: 20220127315Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: January 11, 2022Publication date: April 28, 2022Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
-
Patent number: 11254721Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: GrantFiled: July 29, 2020Date of Patent: February 22, 2022Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
-
Publication number: 20220048967Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: July 2, 2021Publication date: February 17, 2022Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
-
Patent number: 11084861Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: GrantFiled: July 22, 2019Date of Patent: August 10, 2021Assignee: Eli Lilly and CompanyInventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
-
Publication number: 20210221865Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.Type: ApplicationFiled: December 14, 2018Publication date: July 22, 2021Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
-
Publication number: 20210032291Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: ApplicationFiled: July 27, 2020Publication date: February 4, 2021Applicant: The Trustees of the University of PennsylvaniaInventors: John D. LAMBRIS, Hongchang Qu, Daniel Ricklin
-
Publication number: 20210032299Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: July 29, 2020Publication date: February 4, 2021Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
-
Publication number: 20200331980Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.Type: ApplicationFiled: December 14, 2018Publication date: October 22, 2020Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
-
Patent number: 10745442Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: GrantFiled: November 20, 2018Date of Patent: August 18, 2020Assignee: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
-
Publication number: 20200024322Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: July 22, 2019Publication date: January 23, 2020Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Kyle Wynn Sloop, Francis Stafford Willard, Thi Thanh Huyen Tran, Aktham Aburub, Phenil Jayantilal Patel, Amita Datta-Mannan, Xianyin Lai
-
Publication number: 20190077834Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: ApplicationFiled: November 20, 2018Publication date: March 14, 2019Applicant: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
-
Patent number: 10174079Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: GrantFiled: April 19, 2017Date of Patent: January 8, 2019Assignee: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
-
Patent number: 9938335Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).Type: GrantFiled: June 16, 2016Date of Patent: April 10, 2018Assignee: Eli Lilly and CompanyInventors: Adam Robert Mezo, Yanyun Chen, Francisco Alcides Valenzuela, Hongchang Qu
-
Publication number: 20170247413Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: ApplicationFiled: April 19, 2017Publication date: August 31, 2017Applicant: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
-
Patent number: 9630992Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: GrantFiled: September 7, 2012Date of Patent: April 25, 2017Assignee: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
-
Publication number: 20160368960Abstract: The present invention provides glucagon and GLP-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).Type: ApplicationFiled: June 16, 2016Publication date: December 22, 2016Applicant: Eli Lilly and CompanyInventors: Adam Robert MEZO, Yanyun CHEN, Francisco Alcides VALENZUELA, Hongchang QU
-
Patent number: 9371365Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.Type: GrantFiled: February 2, 2015Date of Patent: June 21, 2016Assignee: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Hongchang Qu
-
Publication number: 20150203539Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.Type: ApplicationFiled: February 2, 2015Publication date: July 23, 2015Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John D. LAMBRIS, Hongchang QU
-
Publication number: 20150158915Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.Type: ApplicationFiled: September 7, 2012Publication date: June 11, 2015Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John D. Lambris, Hongchang Qu, Daniel Ricklin